Clinical trial · Observational
ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients
Transarterial Drug-Eluting Chemoembolization for HCC Patients in Korea Using Transradial Approach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a prospective, observational clinical trial designed to evaluate the feasibility, safety, and effectiveness of performing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using a transradial arterial approach. Traditionally, TACE procedures are performed through the femoral artery in the groin, but using the radial artery in the wrist may reduce complications, improve patient comfort, and allow for faster recovery. In this study, eligible patients with unresectable HCC who meet the inclusion criteria-such as preserved liver function (Child-Pugh A), good performance status, and tumors of a certain size and number-will undergo TACE using HepaSphere drug-eluting embolic materials via radial access. No randomization or drug intervention will be assigned by protocol, as the treatment will follow standard clinical practice. The study will follow participants for 12 months to assess technical success, tumor response using imaging criteria (mRECIST), safety outcomes including adverse events, and overall survival. The study is being conducted at Asan Medical Center in Seoul, Korea, and has received Institutional Review Board approval.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE) group
- description
- Patients with hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE) using a transradial arterial approach with HepaSphere microspheres. Participants will be observed prospectively to evaluate the technical success, safety, and tumor response following treatment.
- interventionNames
- Procedure: Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)
Primary outcomes (1)
- measure
- Technical Success Rate
- timeFrame
- Immediately after the procedure
- description
- Defined as successful completion of the planned transarterial chemoembolization (TACE) procedure using transradial access without conversion to transfemoral access.
Secondary outcomes (2)
- measure
- Tumor Response Rate Based on mRECIST
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: \- Inclusion Criteria: * Age between 19 and 80 years * Diagnosed with hepatocellular carcinoma (HCC) * Child-Pugh class A * ECOG performance status 0 or 1 * Tumor size between 3 and 10 cm, with 1 to 7 nodules * Ability to provide written informed consent Exclusion Criteria: * Child-Pugh class B or C * Presence of other malignancies * CKD stage 4 or 5 (eGFR \< 30 mL/min/1.73m²) * Known allergy or contraindication to contrast media * Pregnancy or breastfeeding
References
Publications (1)
- BACKGROUNDFischman AM, Swinburne NC, Patel RS. A Technical Guide Describing the Use of Transradial Access Technique for Endovascular Interventions. Tech Vasc Interv Radiol. 2015 Jun;18(2):58-65. doi: 10.1053/j.tvir.2015.04.002. Epub 2015 Apr 11. PMID 26070616